Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in ...

The most advanced molecules in its pipeline target the IC proteins CD47, a ligand of signal-regulatory protein-α (SIRPα), and PD-L1, a ligand of programmed cell death protein 1 (PD-1 ...

The PFS benefit was demonstrated in patients with either PD-L1-positive or PD-L1-negative tumors. Akeso noted that no new safety signals were identified in this Phase III study. The full data set ...